Related Experiment Video
Updated: Jun 20, 2026

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Targets of protective tumor immunity
1Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA. glenn_dranoff@dfci.harvard.edu
Abstract:
The identification of antigens associated with tumor destruction is a major goal of cancer immunology. Several genetic and biochemical techniques have revealed a broad range of gene products that elicit immune recognition in cancer patients, but the biologic importance of these responses in most cases is poorly understood. While some targets are linked to tumor regressions in the context of adoptive cellular therapies or cancer vaccinations, the possible roles of immunity to most antigens in disease pathogenesis and clinical outcomes remain to be elucidated. One strategy for characterizing antigens that elicit clinically significant immune recognition involves the study of patients who achieve durable clinical benefits from immune treatments. Through this approach, we uncovered the immunogenicity of major histocompatibility chain-related protein A (MICA), which is a ligand for NKG2D, and ERp5, a protein disulfide isomerase involved in MICA shedding. Our findings suggest that components of the NKG2D pathway may be attractive targets for therapeutic monoclonal antibodies.
Insights
Identifying tumor antigens is key in cancer immunology. This study found that major histocompatibility chain-related protein A (MICA) and ERp5 are immunogenic, suggesting potential therapeutic targets.
Area of Science:
- Cancer Immunology
- Immunotherapy
Background:
- Identifying tumor antigens is crucial for understanding cancer immunology and developing effective treatments.
- The clinical significance of immune responses to most tumor antigens remains poorly understood.
- Studying patients with durable responses to immunotherapy can reveal clinically relevant antigens.
Purpose of the Study:
- To identify antigens that elicit clinically significant immune recognition in cancer patients.
- To investigate the immunogenicity of major histocompatibility chain-related protein A (MICA) and ERp5.
- To explore the therapeutic potential of targeting the NKG2D pathway.
Main Methods:
- Analysis of patients achieving durable clinical benefits from immune treatments.
- Investigating the immunogenicity of major histocompatibility chain-related protein A (MICA).
- Studying the role of ERp5 in MICA shedding.
Main Results:
- The study identified major histocompatibility chain-related protein A (MICA) as an immunogenic antigen.
- ERp5, a protein disulfide isomerase, was found to be involved in MICA shedding.
- These findings highlight the importance of the NKG2D pathway in anti-tumor immunity.
Conclusions:
- Major histocompatibility chain-related protein A (MICA) and ERp5 are immunogenic and play a role in anti-tumor immune responses.
- Components of the NKG2D pathway represent promising targets for antibody-based cancer therapies.
- Further research into MICA and ERp5 could lead to novel immunotherapeutic strategies.
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

